|
Adenocarcinoma of the gastroesophageal junction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study.
|
31721447 |
2020 |
|
Adenocarcinoma of the gastroesophageal junction
|
0.100 |
Biomarker
|
disease |
BEFREE |
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
|
31126258 |
2019 |
|
Adenocarcinoma of the gastroesophageal junction
|
0.100 |
Biomarker
|
disease |
BEFREE |
This was a retrospective study conducted across five Korean hospitals in patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma treated with first-line, 3-weekly trastuzumab plus chemotherapy.
|
30535535 |
2019 |
|
Adenocarcinoma of the gastroesophageal junction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma.
|
30516569 |
2019 |
|
Adenocarcinoma of the gastroesophageal junction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Trastuzumab is recommended for the treatment of human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagogastric junction (AEG) in combination with chemotherapy; however, drug resistance has severely affected its clinical application.
|
29456713 |
2018 |
|
Adenocarcinoma of the gastroesophageal junction
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
|
29277796 |
2018 |
|
Adenocarcinoma of the gastroesophageal junction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Regarding the checkpoint inhibitors, based on KEYNOTE 059 multilevel ongoing trial, stratified according to the HER2 and programmed death-ligand (PD-L) 1 status, pembrolizumab was approved for third-line treatment of gastric or gastroesophageal junction adenocarcinoma.
|
29265917 |
2017 |
|
Adenocarcinoma of the gastroesophageal junction
|
0.100 |
Biomarker
|
disease |
BEFREE |
HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.
|
28574779 |
2017 |
|
Adenocarcinoma of the gastroesophageal junction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although trastuzumab improves the outcome of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing gastric or gastroesophageal junction adenocarcinoma (collectively referred to as "gastroesophageal adenocarcinoma"; GEA), no clinical response is observed in a substantial population of patients.
|
27517839 |
2017 |
|
Adenocarcinoma of the gastroesophageal junction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma.
|
27198655 |
2016 |
|
Adenocarcinoma of the gastroesophageal junction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To summarize the usefulness of several recently discovered immunohistochemical markers in the study of gastrointestinal and liver tumors; to suggest the most current and effective immunohistochemical panels addressing common diagnostic challenges for these tumors; to share practical experience and useful tips for human epidermal growth factor receptor 2 testing in gastric and gastroesophageal junction adenocarcinoma and v-raf murine sarcoma viral oncogene homolog B V600E immunohistochemistry in colorectal carcinoma.
|
25549141 |
2015 |
|
Adenocarcinoma of the gastroesophageal junction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma.
|
26625793 |
2015 |
|
Adenocarcinoma of the gastroesophageal junction
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a consequence of the positive results of the ToGA trial, patients with advanced gastric or gastroesophageal junction adenocarcinoma are now routinely tested for HER2.
|
24782605 |
2014 |
|
Adenocarcinoma of the gastroesophageal junction
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.
|
23656792 |
2013 |
|
Adenocarcinoma of the gastroesophageal junction
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
|
22646280 |
2012 |